GLP1R and type 2 diabetes mellitus: One of the strategies recommended is the use of glucose-lowering medications with secondary cardiorenal benefits, including sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), as first- and second-line therapy in T2DM with CKD, respectively [6].